Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)
AURORA, ON, Jan. 30 /CNW/ - Helix BioPharma Corp. announces that at the
Company's Annual General Meeting held on January 29th, 2008, shareholders
adopted all of the resolutions presented by management, appointing KPMG LLP as
auditor, electing Don Segal, John Docherty, Ken Cawkell, Jack Kay, Slawomir
Majewski, and Gordon Lickrish as directors, and approving certain amendments
to the Company's by-laws.
Joining the Helix BioPharma board is Professor Slawomir Majewski, Head of
the Department of Dermatology and Venereology at the Warsaw School of Medicine
in Poland. Professor Majewski's extensive experience in the field of
dermatology, and especially sexually transmitted diseases and skin cancer,
will be of great benefit to the Board of Directors and the senior management
team at Helix.
Retiring from Helix's board are Conor Gunne and Dr. Richard Rossman, who
served as directors of Helix for a number of years. "I would like to
personally thank both Conor and Richard for their valuable contribution to the
Company over the many years and wish them both well in their other endeavors,"
said Don Segal, CEO of Helix BioPharma.
Helix's management would also like to thank its shareholders for their
continued support, and looks forward to the further development of the
Company's new drug products, Topical Interferon Alpha-2b and L-DOS47, in the
A Report of Voting Results in respect of the Meeting will be posted on
the SEDAR website at (www.sedar.com).
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed
on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich
and Stuttgart Stock Exchanges under the same symbol.
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this News
Release. This News Release contains forward-looking statements regarding the
development of the Company's drug products, which statements can be identified
by the words "looks forward, "development" and "developing". Actual results or
events could differ materially from these forward-looking statements and
information due to numerous factors, including without limitation, research &
development risks, intellectual property risks; product liability risks; the
risk of unanticipated expenses, the need for regulatory approvals which is not
assured; the need for clinical trials and uncertainty whether they will occur
or will be successful; and possible changes in business strategy or plans.
These and other risks and uncertainties are contained in Helix's latest Annual
Information Form at www.sedar.com. Forward-looking statements and information
are based on the assumptions and expectations of Helix's management at the
time they are made, and Helix does not assume any obligation, except as
required by law, to update any forward-looking statement or information should
those assumptions or expectations, or other circumstances change.
For further information:
For further information: Investor Relations, Christina Bessant, The
Equicom Group Inc., Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416)
815-0080, Email: email@example.com; Media Relations, David Schull,
Russo Partners LLC, Tel: (212) 845-4271, Fax: (212) 845-4260, Email: